文献速递消化系统肿瘤

贝伐珠单抗联合mFOLFOX6一线治疗RAS突变不可切除结直肠癌肝转移的随机对照研究

Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2020-08-04

BECOME研究为随机对照试验,纳入241例RAS突变不可切除结直肠癌肝限制性转移患者,比较贝伐珠单抗联合mFOLFOX6与单用mFOLFOX6一线治疗。联合组肝转移R0切除率22.3%显著高于单药组5.8%(P<.01),客观缓解率、无进展生存和总生存均显著改善。

要点

  • 贝伐珠单抗联合mFOLFOX6显著提高RAS突变不可切除结直肠癌肝转移的R0切除率(22.3% vs 5.8%)。
  • 联合组客观缓解率54.5%优于单药组36.7%,中位PFS 9.5个月优于5.6个月。
  • 联合组中位OS 25.7个月优于20.5个月,蛋白尿和高血压发生率增加但可管理。

核心结论

  • 对于初始不可切除的RAS突变结直肠癌肝限制性转移患者,贝伐珠单抗联合mFOLFOX6较单用mFOLFOX6提高肝转移可切除性、缓解率和生存。

研究设计与样本

  • 肝转移可切除性由当地多学科团队判定,主要终点为实际转为R0切除的肝转移患者比例。

主要发现

  • 联合组肝转移R0切除率为22.3%(27/121),单药组为5.8%(7/120),差异有统计学意义(P<.01)。
  • 联合组客观缓解率为54.5%,单药组为36.7%(P<.01)。
  • 联合组中位无进展生存期为9.5个月,单药组为5.6个月(P<.01)。
  • 联合组中位总生存期为25.7个月,单药组为20.5个月(P=.03)。
  • 联合组蛋白尿发生率9.9% vs 3.3%(P=.04),高血压发生率8.3% vs 2.5%(P<.05)。

临床怎么用

  • RAS突变不可切除结直肠癌肝限制性转移患者一线可考虑贝伐珠单抗联合mFOLFOX6以提高肝转移R0切除机会。
  • 治疗期间需监测蛋白尿和高血压等贝伐珠单抗相关不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant unresectable colorectal liver metastases. METHODS: From October 2013 to December 2017, patients with RAS mutant unresectable liver-limited metastases from colorectal cancer were randomly assigned to receive mFOLFOX6 plus bevacizumab (arm A) or mFOLFOX6 alone (arm B). The resectability of liver metastases was determined by a local multidisciplinary team. The primary end point was the actual rate of patients converted to R0 resection for liver metastases. Secondary end points included tumor response, survival, and toxicity. The block randomization method was used. RESULTS: The intention-to-treat population comprised 241 patients. A total of 121 patients were randomly assigned to arm A and 120 to arm B. The median follow-up time was 37.0 months for all patients. The R0 resection rates for liver metastases were 22.3% (27 of 121 patients) in arm A and 5.8% (7 of 120 patients) in arm B, with a significant difference (P < .01). Patients in arm A had significantly better objective response rates (54.5% v 36.7%; P < .01), median progression-free survival (9.5 v 5.6 months; P < .01) and median overall survival (25.7 v 20.5 months; P = .03) compared with those in arm B. The addition of bevacizumab was associated with more frequent proteinuria (9.9% v 3.3%; P = .04) and hypertension (8.3% v 2.5%; P < .05). CONCLUSION: For patients with initially unresectable RAS mutant colorectal liver metastases, bevacizumab combined with mFOLFOX6 increased the resectability of liver metastases and improved response rates and survival compared with mFOLFOX6 alone.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tang W, Ren L, Liu T, et al. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial. J Clin Oncol. 2020. PMID: 32749938. doi:10.1200/JCO.20.00174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。